The Interthyr Corporation (IC) develops diagnostics and therapeutics for endocrine diseases, autoimmune-inflammatory diseases and cancer. Our goal is to improve health care in humans and animals.

IC genetically engineers cells to create functional bioassays that better measure active disease processes.IC has developed bioassays that measure functional autoantibodies in patients with Graves' disease, an autoimmune disease of the thyroid, in which the body's immune system produces antibodies against the thyrotropin (TSH) receptor. These assays in kit form are licensed to Diagnostic Hybrids, Inc. (DHI). A 3rd generation assay using a chimeric TSH receptor that largely measures only stimulating autoantibodies has been FDA approved and was released commercially as the Thyretain Assay in 2009. For the first time, an assay with prognostic significance in Graves' orbitopathy, exophthalmos, and in response to immunosuppressive therapy exists.

Currently under development: (i) An assay to measure inhibitor antibodies in Graves', Hashimoto's, and idiopathic myxedema and (ii) an assay to measure vulnerable plaques in atherosclerotic cardiovascular disease

IC's work in therapeutics has focused on the hypothesis that environmental stimuli initiate autoimmune-inflammatory diseases and cancer by activating abnormal Toll-like receptor (TLR) signaling in non-immune cells, inducing abnormal or aberrant MHC gene expression and cytokine production. IC has developed several agents that inhibit this environmental induction process and reverse or prevent multiple animal models of disease. Currently, IC is investigating the use of these agents for the treatment of pancreatic cancer, malignant melanoma, Types 1 and 2 Diabetes, colitis, toxic shock, Graves' disease and atherosclerosis.

In 2009, IC was awarded a 2.6 million dollar STTR Phase II grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health to pursue the development of these new drugs.